Journals / Jinekoloji Obstetrik Pediatri ve Pediatrik Cerrahi Dergisi / 2013 / Cilt: 5 - Sayı: 1

Parvovirus B19 Infection During Pregnancy: Clinical Course and Prognosis

Gebelikte Parvovirus B19 Enfeksiyonu: Klinik Seyir ve Prognoz

Pages
1–6
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Aim of this study was to review perinatal Parvovirus B19 infection and its probable feto-maternal effects.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Parvovirus B19 is a small DNA virus, and frequently affects the children.
📊
Key Findings & Data:The incidence in pregnancy is 3 percent.
💡
Conclusion & Impact:Aim of this study was to review perinatal Parvovirus B19 infection and its probable feto-maternal effects.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Parvovirus B19 is a small DNA virus, and frequently affects the children. Adults can contract infection but, the clinical picture is subacute or mild. The incidence in pregnancy is 3 percent. Although perinatal infection is usually asymptomatic, the virus might lead to fetal loss or hydrops fetalis. However, the infection in pregnancy is usually associated with normal pregnancy outcome. The diagnosis is suspected with clinical symptoms and it is confirmed by serology. There is no specific treatment. Symptomatic treatment is shown to decrease perinatal mortality. Aim of this study was to review perinatal Parvovirus B19 infection and its probable feto-maternal effects.

Özet

Parvovirus B19 küçük bir DNA virusudur ve sıklıkla çocukları etkiler. Erişkinler enfeksiyona yakalanabilir ama klinik tablo subakut ya da hafiftir. Genel popülasyondaki B19 IgG antikor prevalansı yaşa bağlı olarak değişir. Çocukluk çağında % 15-60 arasında olan antikor prevalansı, erişkinlerde % 30-60, geriyatrik yaş grubunda ise % 85'tir. Gebelikteki insidans % 3'tür. Perinatal enfeksiyonun genellikle asemptomatik olmasına rağmen, virus fetal kayıp ya da hidrops fetalise yol açabilir. Bununla birlikte, gebelikteki enfeksiyon genellikle normal gebelik sonlanması ile birliktedir. Tanıdan klinik semptomlarla şüphelenilir ve kesin tanı laboratuvar bulgularıyla konur. Spesifik bir tedavisi yoktur. Semptomatik tedavinin perinatal mortaliteyi azalttığı gösterilmiştir. Bu çalışmanın amacı perinatal Parvovirus B19 enfeksiyonunu ve olası feto-maternal etkilerini gözden geçirmektir.

🔖

Cite This Article

YAPÇA, Ö. E., YILMAZ, N., KARA, M., BALCI, M. (2022). Parvovirus B19 Infection During Pregnancy: Clinical Course and Prognosis. Jinekoloji Obstetrik Pediatri ve Pediatrik Cerrahi Dergisi, Cilt: 5 - Sayı: 1, 1–6. https://ajindex.com/articles/558521

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Cossart YE, Field AM, Cant B, Widdows D. Parvovirus-like particles in human sera. Lancet 1975;1:72. http://dx.doi.org/10.1016/S0140-6736(75)91074-0
  2. Carrington D, Gilmore DH, Whittle MJ, Aitken D, Gibson AA, Patrick WJ, et al. Maternal serum alpha-fetoprotein--a marker of fetal aplas- tic crisis during intrauterine human parvovirus infection. Lancet 1987;1(8530):433-5. http://dx.doi.org/10.1016/S0140-6736(87)90129-2
  3. Naides SJ, Weiner CP. Antenatal diagnosis and palliative treatment of non-immune hydrops feta- lis secondary to fetal parvovirus B19 infection. Prenat Diagn 1989;9(2):105-14. http://dx.doi.org/10.1002/pd.1970090205 PMid:2466284 Woolf AD, Campion GV, Chishick A, Wise S, Cohen BJ, Koluda PT, et al. Clinical manifesta- tions of human parvovirus B19 in adults. Arch Intern Med 1989;149:1153-6. http://dx.doi.org/10.1001/archinte.1989.003900 50111022 PMid:2541666 Cartter ML, Farley TA, Rosengren S, Quinn DL, Gillespie SM, Gary GW, et al. Occupational risk factors for infection with parvovirus B19 among pregnant women. J Infect Dis 1991;63:282-5. http://dx.doi.org/10.1093/infdis/163.2.282 PMid:1846391 Potter CG, Potter AC, Hatton CS, Chapel HM, Anderson MJ, Pattison JR, et al. Variation of erythroid and myeloid precursors in the marrow and peripheral blood of volunteer subjects infec- ted with human parvovirus (B19). J Clin Invest 1987;9:1486-92. http://dx.doi.org/10.1172/JCI112978 PMid:3033026 PMCid:424424 Anderson MJ, Higgins PG, Davis LR, Willman JS, Jones SE, Kidd IM, et al. Experimental par- voviral infection in humans. J Infect Dis 1985;152:257-65. http://dx.doi.org/10.1093/infdis/152.2.257 PMid:2993431 Young N, Harrison M, Moore J, Mortimer P, and Humphries RK. Direct demonstration of the human parvovirus in erythroid progenitor cells infected in vitro. J Clin Invest 1989;84:1114-23. PMid:2551923 PMCid:329767 Public Health Laboratory Service Working Party on Fifth Disease. Prospective study of human parvovirus B19 infection in pregnancy. Br Med J 1990;30:1166-70.
  4. Van Elsacker-Niele AM, Salimans MM, Weiland HT, Vermey-Keers C, Anderson MJ, et al. Fetal pathology in human parvovirus B19 infection. Br J Obstet Gynaecol 1989;96:768-75. http://dx.doi.org/10.1111/j.1471-0528.1989. tb03314.x Brown T, Anand A, Ritchie LD, Crewley JP, Reid TM. Intrauterine parvovirus infection asso- ciated with hydrops fetalis. Lancet 1984;2:1033- 4. http://dx.doi.org/10.1016/S0140-6736(84)91126-7
  5. Enders M, Weidner A, Zoellner I, Searle K, Enders G. Fetal morbidity and mo